{{Rsnum
|rsid=4726075
|Gene=PRKAG2
|Chromosome=7
|position=151638174
|Orientation=plus
|GMAF=0.1198
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PRKAG2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 74.3 | 22.1 | 3.5
| HCB | 98.5 | 1.5 | 0.0
| JPT | 98.2 | 1.8 | 0.0
| YRI | 53.1 | 40.8 | 6.1
| ASW | 56.1 | 36.8 | 7.0
| CHB | 98.5 | 1.5 | 0.0
| CHD | 98.2 | 1.8 | 0.0
| GIH | 89.1 | 9.9 | 1.0
| LWK | 60.0 | 34.5 | 5.5
| MEX | 77.6 | 20.7 | 1.7
| MKK | 53.8 | 40.4 | 5.8
| TSI | 67.6 | 30.4 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4726075
|Name_s=
|Gene_s=PRKAG2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00006. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109447
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4726075
|overall_frequency_n=23
|overall_frequency_d=128
|overall_frequency=0.179688
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=24
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}